中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
12期
1608-1609
,共2页
慢性阻塞性肺疾病%噻托溴铵%异丙托溴铵
慢性阻塞性肺疾病%噻託溴銨%異丙託溴銨
만성조새성폐질병%새탁추안%이병탁추안
COPD%Tiotropium%Ipratropium bromide
目的 探讨噻托溴铵治疗稳定期慢性阻塞性肺疾病(COPD)的疗效.方法 回顾性分析240例稳定期COPD患者的临床资料.根据治疗方法分为噻托溴铵组和异丙托溴铵组,每组120例.比较治疗前和治疗2周后肺功能及临床症状改善情况.结果 噻托溴铵组的肺功能指标一秒用力呼气量(FVC),用力肺活量(FEV1)、FEV1/FVC及FEV1占预计值的百分比分别为(3.64±0.58)L、(2.53±0.25)L、(62.40±9.42)%、(58.24±4.83)%,均较异丙托溴铵组的(3.14±0.36)L、(1.91±0.23)L、(56.50±7.36)%、(50.41±5.54)%明显改善(t=2.037、1.875、2.616、2.945,均P<0.05),且前者的临床症状亦比后者改善明显,差异有统计学意义(H=5.990,P<0.05).结论 噻托溴铵治疗治疗稳定期COPD,具有良好的临床效果,值得临床推广应用.
目的 探討噻託溴銨治療穩定期慢性阻塞性肺疾病(COPD)的療效.方法 迴顧性分析240例穩定期COPD患者的臨床資料.根據治療方法分為噻託溴銨組和異丙託溴銨組,每組120例.比較治療前和治療2週後肺功能及臨床癥狀改善情況.結果 噻託溴銨組的肺功能指標一秒用力呼氣量(FVC),用力肺活量(FEV1)、FEV1/FVC及FEV1佔預計值的百分比分彆為(3.64±0.58)L、(2.53±0.25)L、(62.40±9.42)%、(58.24±4.83)%,均較異丙託溴銨組的(3.14±0.36)L、(1.91±0.23)L、(56.50±7.36)%、(50.41±5.54)%明顯改善(t=2.037、1.875、2.616、2.945,均P<0.05),且前者的臨床癥狀亦比後者改善明顯,差異有統計學意義(H=5.990,P<0.05).結論 噻託溴銨治療治療穩定期COPD,具有良好的臨床效果,值得臨床推廣應用.
목적 탐토새탁추안치료은정기만성조새성폐질병(COPD)적료효.방법 회고성분석240례은정기COPD환자적림상자료.근거치료방법분위새탁추안조화이병탁추안조,매조120례.비교치료전화치료2주후폐공능급림상증상개선정황.결과 새탁추안조적폐공능지표일초용력호기량(FVC),용력폐활량(FEV1)、FEV1/FVC급FEV1점예계치적백분비분별위(3.64±0.58)L、(2.53±0.25)L、(62.40±9.42)%、(58.24±4.83)%,균교이병탁추안조적(3.14±0.36)L、(1.91±0.23)L、(56.50±7.36)%、(50.41±5.54)%명현개선(t=2.037、1.875、2.616、2.945,균P<0.05),차전자적림상증상역비후자개선명현,차이유통계학의의(H=5.990,P<0.05).결론 새탁추안치료치료은정기COPD,구유량호적림상효과,치득림상추엄응용.
Objective To explore the clinical effect of inhaling tiotropium in treatment of patients with stable chronic obstructive pulmonary disease.Methods The clinical data of 240 patients with stable chronic obstructive pulmonary disease were retrospectively analyzed,and they were divided into two groups,the group treated with tiotropium and the group treated with ipratropium bromide(n = 120 in each group).The lung function was detected 2 weeks before and after the treatment, and the clinical symptoms were observed.Results FVC, FEV1, FEV1/FVC, and FEV1/predictive value of the tiotropium group were(3.64 ±0.58) L, (2.53 ±0.25) L, (62.40 ±9.42)% ,(58.24 ± 4.83)% respectively,much higher than(3.14 ±0.36)L,( 1.91 ±0.23)L,(56.50 ±7.36)%,(50.41 ±5.54)% of the ipratropium bromide group(t =2.037,1.875,2.616,2.945,all P<0.05) ,and the clinical symptoms were better changed in tiotropium group than in ipratropium bromide group (H = 5.990, P < 0.05 ).Conclusion Tiotropium could effectively improve lung function and clinical symptoms in patients with stable COPD.
